Henlius Seeks To Add RA Indication To Chinese Rituximab

HLX01 Biosimilar Was First Approved In China Under New Pathway

 
• By Dave Wallace
  
Rheumatoid arthritis
Henlius is seeking to add the rheumatoid arthritis indication to its rituximab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products